It is an extended release analgesic, given at the beginning of a procedure. Liposomal Bupivacaine’s pain killing effects last for a duration of 72 hours. In hospitals, anesthesiologists could use this new analgesic to reduce the use of opioid use because a single application would provide analgesic effects after the lumbar spinal fusion surgery.
I will conduct a quantitative, quasi-experimental study comparing patients’ level of postoperative pain when treated with liposomal bupivacaine against patients treated with prescription opioids. I will study the efficiency of liposomal bupivacaine against prescription opioids in treating postoperative pain in Well Star patients receiving a lumbar spinal fusion surgery. The study will address the question, how can the use of liposomal bupivacaine reduce the use of prescription opioids to treat postoperative pain in Well Star